Jane Liang White

Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial

Yi‐Long Wu, Ying Cheng, Xiangdong Zhou et al. · The Lancet Oncology · 2017 · 1.2K citations

Medicine, Oncology, Pharmacology +12

Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer and <i>EGFR</i>-Activating Mutations

Tony Mok, Ying Cheng, Xiangdong Zhou et al. · Journal of Clinical Oncology · 2018 · 436 citations

Medicine, Oncology, Pharmacology +12

Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long‐term survival follow‐up from the randomized, phase 3 INO‐VATE study

Hagop M. Kantarjian, Daniel J. DeAngelo, Matthias Stelljes et al. · Cancer · 2019 · 329 citations · Full text

Medicine, Oncology, Pharmacology +15

Transcriptional regulation of the <i>redD</i> transcriptional activator gene accounts for growth‐phase‐dependent production of the antibiotic undecylprodigiosin in <i>Streptomyces coelicolor</i> A3(2)

Eriko Takano, Hugo Gramajo, Eckhard Strauch et al. · Molecular Microbiology · 1992 · 200 citations · Full text

Life Sciences, Microbiology, Molecular Biology +15

bldA dependence of undecylprodigiosin production in Streptomyces coelicolor A3(2) involves a pathway-specific regulatory cascade

Jane Liang White, Mervyn J. Bibb · Journal of Bacteriology · 1997 · 155 citations

Life Sciences, Biology, Microbiology +15